Roche touts CHMP nod for Hem­li­bra; Alder rais­es $200M for mi­graine drug launch

Roche’s $RHH­BY Hem­li­bra has just scored a pos­i­tive opin­ion from CHMP, as it con­tin­ues to tout the he­mo­phil­ia drug as a po­ten­tial block­buster. The …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.